El estudio original de Raun y colaboradores (European Journal of Endocrinology, 1998) caracteriz analticamente su selectividad sobre el receptor GHS-R1a
Rickettsia and their close relatives are obligate to the host cell cytosol, where they parasitize over fifty metabolites 10,11
30,31 Overall, the 2 studies concluded that mitapivat was safe and tolerable in participants with SCD, and a phase 2/3 multicenter study, RISE UP (Table 1), is in progress, with primary end points of hemoglobin response, treatment-emergent adverse events (phase 2), and annualized rate of VOC (phase 3)
(eds) Principles of Biochemistry (Pearson Press, 2006)
Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH